Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.

Garg DK, Wei J

Cureus22 Jun 2026

PMID42488278PMCIDPMC13391223DOI10.7759/cureus.111313PepBankPUB-42488278

Summary

This case reviews the use of a Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) in a young man presenting with excessive hunger and rapid weight gain compounded by an underlying rare form of genetic obesity, Smith-Magenis syndrome. The patient had, prior to presentation, seen an accelerated and persistent weight gain over the last five years despite attempts at portion control and behavior modification. Due to concerns of worsening metabolic disease, including prediabetes, dyslipidemia, and fatty liver disease, we started the patient on daily liraglutide and gradually titrated to the maximum dose over five months. He was able to tolerate the medication without severe gastrointestinal side effects, and alongside lifestyle and behavioral modifications, the patient lost 22.2 kg (49 lbs) over the course of 11 months. To our knowledge, there is only one other published case report documenting the use of GLP1RA therapy in a patient with Smith-Magenis syndrome.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanCase report or seriesSafety outcome
In a young man with Smith-Magenis syndrome, daily liraglutide was tolerated without severe gastrointestinal side effects.
In plain wordsIn one young man with Smith-Magenis genetic obesity, liraglutide was tolerated without severe stomach or bowel side effects.
Peptide
Liraglutide
Outcome
Not applicableSevere gastrointestinal side effects
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
He was able to tolerate the medication without severe gastrointestinal side effects, and alongside lifestyle and behavioral modifications, the patient lost 22.2 kg (49 lbs) over the course of 11 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This case reviews the use of a Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) in a young man presenting with excessive hunger and rapid weight gain compounded by an underlying rare form of genetic obesity, Smith-Magenis syndrome.
Summary · context
Due to concerns of worsening metabolic disease, including prediabetes, dyslipidemia, and fatty liver disease, we started the patient on daily liraglutide and gradually titrated to the maximum dose over five months.
Show in the study text Report a problemFND-4248827801

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In one young man with Smith-Magenis genetic obesity, liraglutide alongside lifestyle and behavioral modifications was followed by 22.2 kg (49 lb) weight loss over 11 months.
In plain wordsIn one young man with Smith-Magenis genetic obesity, liraglutide alongside lifestyle and behavioral modifications was followed by 22.2 kg weight loss over 11 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Measurements
body weight change
−22.2 kg
over 11 months
Source sentences
Summary
He was able to tolerate the medication without severe gastrointestinal side effects, and alongside lifestyle and behavioral modifications, the patient lost 22.2 kg (49 lbs) over the course of 11 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This case reviews the use of a Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) in a young man presenting with excessive hunger and rapid weight gain compounded by an underlying rare form of genetic obesity, Smith-Magenis syndrome.
Summary · context
Due to concerns of worsening metabolic disease, including prediabetes, dyslipidemia, and fatty liver disease, we started the patient on daily liraglutide and gradually titrated to the maximum dose over five months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4248827802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.